US FDA Eager To INTERACT With Start-Ups, Not Check Boxes

A US FDA webinar for start-up sponsors showcased staff who sound enthusiastic about helping drug developers advance their projects, while also emphasizing the importance of early and continual engagement with the agency.

meeting
The FDA wants start-ups to take advantage of all meeting opportunities. • Source: Shutterstock

The new INTERACT meeting process can be a critical step for start-up sponsors to avoid early stumbles in their attempts to move into human trials, US Food and Drug Administration officials emphasized during a recent webinar offering “Regulatory Do’s and Don’ts” for small businesses.

Key Takeaways
  • FDA officials want start-up sponsors to take advantage of opportunities to meet with the agency.

  • The agency said INTERACT meetings are not...

“I highly recommend you take advantage of the meeting opportunities” outlined during the webinar, Center for Biologics Evaluation and Research CMC Reviewer Karin Knudson said. “In particular for early-phase studies,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By 

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.